Loading
Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.
Lerotinib is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Specification: 50 mg/capsule and 150 mg/capsule. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04415853 (Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer), in oesophageal cancer. The largest, NCT04415853, plans to enrol 416 participants with primary completion was scheduled for 2026-08 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Lerotinib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Lerotinib" OR ABSTRACT:"Lerotinib" OR TITLE:"Z650" OR ABSTRACT:"Z650") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lerotinib, not a curated reading list.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.